Xinbang Pharmaceutical released its 2026 interim report on August 27. During the reporting period, both revenue and net profit declined, but operating cash flow improved significantly, and the company introduced a semi-annual cash dividend plan. Data shows the company achieved operating revenue of 2.467 billion yuan, down 13.29 percent year on year; net profit attributable to the parent company was 99 million yuan, down 7.10 percent year on year; and non-GAAP net profit attributable to the parent company was 77 million yuan, down 28.13 percent year on year. Net cash flow from operating activities was 401 million yuan, up 76.45 percent year on year. The company plans to distribute a cash dividend of 0.3 yuan per 10 shares, tax included, to all shareholders. In terms of business structure, pharmaceutical distribution remained the largest revenue source, with revenue of 1.746 billion yuan, accounting for 59.17 percent of the total and down 18.33 percent year on year; the medical services segment posted revenue of 730 million yuan, accounting for 24.76 percent and down 7.65 percent year on year; and the pharmaceutical manufacturing segment posted revenue of 472 million yuan, accounting for 16.01 percent and down 3.85 percent year on year. The decline in performance was mainly affected by drug centralized procurement price cuts and medical insurance payment reform, while the improvement in cash flow benefited from the company's strengthened collection management and cost control.
Guizhou Xinbang Pharmaceutical Co LtdOperating cash flow rose 76.45% on stronger collection management and cost control, and a semi-annual cash dividend was introduced.
